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According to the International Diabetes 
Federation in Ukraine, the number of pa-
tients with diabetes mellitus (DM) between 
the ages of 20 and 79 years is about 7 % of 
the total population [1], with an increasing es-
timate of approximately 629 million patients 
worldwide by 2045 [2]. DM is a major cause of 
blindness, kidney failure, heart attacks, stroke 
and lower limb amputation [3]. DM related ul-
cers rank first among lower extremity ulcers, 
which in most cases result to sensitivity loss 
[4]. Diabetic neuro- and angiopathy are major 
factors causing diabetic foot ulcers (DFU) [5], 
resulting from ischemic reduction of oxygen 
and nutrients supply to the ulcerous site, thus 
hindering the optimal wound healing process 
in such patient cohorts. In oxygen and nutrient 
deprived states, epithelial cells in the ulcerous 
site fail to release vital healing factors such 
as vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor (PDGF) [6]. 
Some growth factors such as epidermal growth 
factor (EGF), granulocyte-colony stimulating 
factor (GCSF), nerve growth factor (NGF) and 
VEGF have been evaluated in patients with 
DFU [7, 8]. In recent studies a pool of growth 
factors from auto logous plasma rich growth fac-
tors were analyzed [9, 10].
Health Related Quality of life (HRQoL) 
research has become an integral part of mod-
ern medicine. The World Health Organization 
(WHO) recommends the use of the following 
 basic HRQoL criteria: physical, psychologi-
cal, level of autonomy, social life and environ-
ment [11], thus the EuroQol-5D-5L (Ukrainian 
Version for Ukraine) questionnaire develo-
ped by the European Quality of Life Study 
(EuroQol Group), which was officially approved, 
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was used to assess patients’ quality of life in 
this study. This questionnaire demonstrates 
both physical and psycho-emotional indicators 
as well as permits quality of life assessments at 
different stages of the treatment process.
The aim of this study is to evaluate the effi-
cacy of combined photodynamic therapy (PDT) 
and plasma rich growth factors (PRGFT) the-
rapy on the quality of life improvement in pa-
tients with diabetic foot syndrome. 
MATERIALS AND METHODS
The study included 61 outpatients with 
type 2 DM with Wagner grade II diabetic foot 
syndrome, who gave informed consent to par-
ticipate in the study in accordance with the 
world medical association (WMA) Helsinki 
Declaration — Ethical Principles for Medical 
Research Involving Human Subjects, 2013. 
The inclusion criteria for the groups were 
the presence of trophic ulcers with an area 
≤ 5 cm2 (1st group — 4.39 ± 0.5 cm2, 2nd group — 
4.45 ± 0.45 cm2), HbA1c ≤ 7 % (1st group — 
6,9 %, 2nd — 6,8 %).
Depending on the regimen of the proposed 
therapy, patients were divided into two groups 
comparable in clinical status, age (1st group — 
60,53 ± 9,98 years, 2nd — 62,23 ± 8,64 years), 
gender (1st group — males = 7, females = 23; 
2nd — males = 8, females = 23).
Antihyperglycemic treatment in the both 
groups (n = 61) included combination therapy: 
long-acting insulin + metformin — 22.95 % 
(14 patients), sulfonylurea + metformin — 
63.93 % (39 patients), dipeptidyl peptidase 
4 inhibitor + metformin — 6.56 % (4 patients), 
sulfonylurea + sodium — glucose cotransporter 
2 inhibitor — 3.28 % (2 patients), and monothe-
rapy with metformin — 3.28 % (2 patients) [12]. 
Glucose-lowering therapy was supplemen-
ted with antibiotics (according to the results of 
microbiological examination of the discharge), 
while wound debridement (1st group), in the 
2nd group (n = 31) standard therapy (ST) was 
supplemented by PDT and PRGFT procedures.
Initially patients were prescribed PDT 
using a laser machine «Lika-Surgeon M» 
(Photonica-Plus, Ukraine) with a wavelength 
of 660 nm in a continuous regiment every other 
day (8 procedures). Methylene blue 1 % aque-
ous solution as a photosensitizer was used.
After 2 weeks post wound surface clean-
ing and transitioning to the granulation phase, 
PRGFT was added to treatment process. The 
procedures were performed once a week, a total 
of 4 treatment course procedures.
In order to assess quality of life dyna-
mics, all patients were interviewed using the 
EuroQol-5D-5L survey instrument, which con-
sists of a EQ-5D descriptive system followed 
by the EQ visual analogue scale (EQ VAS) [13, 
14]. In the descriptive section, health status 
is measured in five dimensions (5D); mobility, 
self-care, usual activities, pain/discomfort, and 
anxiety/depression. Scores from 1 to 5 were di-
vided into two subgroups, where scores 1, 2, 
and 3 corresponded to the overall quality of life 
scores above average; and 4 and 5 were below 
average.
The S(AD)SAD (Size (Area, Depth), Sepsis, 
Arteriopathy, Denervation) classification was 
used to evaluate clinical status dynamics, 
which included 4 categories of 2 points, with 
a maximum of 30 points characterizing the 
most severe condition [15]. The evaluation 
criteria included: size (0 — skin intact; 2 — 
< 1 cm2; 4 — 1–3 cm2; 6 — > 3 cm2) and depth 
of wound surface (0 — skin intact; 2 — super-
ficial — involving skin and subcutaneous tis-
sues but not reaching the tendon, periosteum 
or joint capsule; 4 — penetrating the tendon, 
periosteum or joint capsule; 6 — involving bone 
or joint spaces), presence of infectious process 
(0 — no infection; 2 — superficial infection, in-
dicated by slough or exudate, but without clini-
cal suspicion of cellulitis or osteomyelitis, also 
tinea pedis; 4 — cellulitis; 6 — osteomyelitis), 
degree of angiopathy (evaluated by the ankle-
brachial index (ABI), where 1 point was for 
0.7–0.9, and 2 points — for ≤ 0.6) and neuro-
pathy (assessed using the Neurological Deficit 
Scale — NDS, where a score of 0 indicated no 
neuropathy, a score of 1 — moderate neuropa-
thy, and a score of 2 — severe neuropathy).
The survey was performed in both groups 
at the beginning of treatment (EuroQol — 
1 and S (AD) SAD — 1), after 2 weeks (Euro-
Qol — 2 and S (AD) SAD — 2), after 6 weeks 
of treatment (EuroQol — 3 and S (AD) 
SAD — 3).
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To evaluate trophic ulcer healing dynamics, 
a Lesion Meter app was used. Measurements 
were made at each patient visit. Data for each 
patient were automatically stored in separate 
folders.
Statistical analysis was performed with 
Windows 10 — Office Professional Plus soft-
ware (Agreement ID: V0731528) with the use 
of parametric and non-parametric methods 
of variation statistics. Shapiro–Wilk test was 
applied to test normality of parameters in the 
study. Two-sample Student’s t-test was used 
to determine the significantly changed bet-
ween groups with a probability mean of 0.05. 
Relative change method was used to compare 
ulcer healing dynamics in the two groups.
RESULTS AND THEIR DISCUSSION
Clinical status evaluation in the 1st group 
demonstrated the average total score at base-
line to be 13.97 points according to S(AD) SAD 
classification, after 2 weeks — 13.20 (improve-
ment by 5.51 %), after 6 weeks — 7.83 (im-
provement by 43.95 %) (p > 0,05) (Tab. 1).
Clinical status improvement in patients 
in the 1st group after PDT was achieved by 
a 19.89% inflammation reduction. Other S(AD) 
SAD categories had significant positive dy-
namics. The results obtained following PRGFT 
stimulation of the epithelium in the second 
stage showed a 30.95% decrease of the ulcer 
defect area, depth — by 5.00 %, improvement 
of angiopathy indices — by 28.93 % and neu-
ropathy signs — 15.54 % (p > 0,05).
In the 2nd group, baseline average total 
score was 13.91 points, after 2 weeks — 12.29 
(improvement by 11.65 %), after 6 weeks — 
6.36 points (improvement by 54.27 %) (p > 0,05) 
(Tab. 2).
The same positive clinic dynamics in the 
2nd group post PDT were achieved with more 
obvious improvement of up to 42.52 %, while 
positive dynamics were observed in other cat-
egories. PRGFT performed at the second stage 
as part of the combined treatment resulted 
in: 53.05 % decrease of defective ulcer area, 
depth — by 11.00 %, improvement indices in 
angiopathy category — by 43.29 %, in the neu-
ropathic category — by 22.10 % (p < 0,05). 
An estimation of quality of life dynamics in 
the 1st group showed significant improvement 
in «mobility» by 14.78 % after 2 weeks, after 
6 weeks — by 27.58 %; in the «usual activities» 
category — by 2.09 % after 2 weeks, and after 
Table 1 
S(AD)SAD evaluation of ulcers healing dynamics  










At baseline 4,2 2,0 3,87 1,97 1,93
2 weeks 4,2 2,0 3,10 1,97 1,93
6 weeks 2,9* 1,9 0* 1,4 1,63
* statistically significant difference compared to the baseline (p < 0.05).
Table 2 
S(AD)SAD evaluation of ulcers healing dynamics  
in the 2nd group






At baseline 4,26 2,0 3,81 1,94 1,9
2 weeks 4,26 2,0 2,19* 1,94 1,9
6 weeks 2,0* 1,78* 0* 1,1* 1,48*
* statistically significant difference compared to the baseline (p < 0.05).
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6 weeks — by 4.19 %; in  «pain/discomfort» — 
by 9.9 % after 2 weeks, after 6 weeks — by 
25.08 % (p > 0,05). In the «self-care» and «an-
xie ty/depression» categories, significant im-
provement in the quality of life was achieved 
only after 6 weeks — by 24.9 % and 17.18 % 
(p > 0,05), respectively (Tab. 3).
In the 2nd group, quality of life dynamics 
after PDT demonstrated a 17.5 % improved 
ave rage score in «mobility», 9.15 % in «usual 
activities» and by 15.15 % in the «pain/discom-
fort» categories. Following PRGFT, improve-
ment was achieved by 43.5 % in the «physical 
activity» category, 22.54 % in the «household 
activity» and by 33.67 % in the «pain/discom-
fort» categories (p < 0,05) (Tab. 4).
Unlike patients in the 1nd group, earlier po-
si tive quality of life dynamics in the 2nd group 
was obtained after PDT in the «anxiety/depres-
sion» and «self-care» categories by 19.74 % and 
7.85 % respectively, with further improvement 
after PRGFT by 68.46 %, and in the «self-care» 
after 6 weeks — by 28.09 % (p > 0.05).
Further quality of life evaluation with 
Vi sual Analog Scale VAS in the 1st group re-
vealed a baseline total score of 41.73 points, 
after 2 weeks’ — 58.33 score points and after 
6 weeks — 62.37 score points, with appropri-
ate improvement by 28.46 % and 33.09 % after 
standard treatment (p < 0,05). In the 2nd group, 
29.97 % post PDT and 42.69 % post PRGFT 
improvements were obtained (p < 0,05).
Discussion. Non-healing trophic ulcers in 
patients with diabetes mellitus significantly 
impairs quality of life and inhibits both physi-
cal and psychological status. Using PDT as 
combined therapy for chronic ulcers in DM pa-
tients resulted in complete purification of the 
wound surfaces in shorter time periods com-
pared to ST. This thus influenced all quality 
of life indicators according to EuroQol scale, 
including the category of «mobility» (2.72 % im-
Таble 3 
EuroQol-5D-5L evaluation dynamics in the 1st group








(6 and  
2 weeks)
Morbility 2,03 1,73 – 15 1,47* – 28
Self-care 2,53 2,53 0 1,90* – 25
Usual activities 1,43 1,4 –2 1,37 – 5
Pain / discomfort 3,03 2,73 – 10 2,27* – 25
Anxiety/depression 3,9 3,9 0 3,23* – 17
VAS 41,73 58,33* 40 62,37* 49
* statistically significant difference compared to the baseline (p < 0.05).
Таble 4 
EuroQol-5D-5L evaluation dynamics in the 2nd group








(6 and  
2 weeks)
Morbility 2,0 1,65* – 18 1,13* – 44
Self-care 2,42 2,23 – 8 1,74* – 28
Usual activities 1,42 1,29 – 9 1,1* – 23
Pain / discomfort 2,97 2,52 – 15 1,97* – 34
Anxiety/depression 3,9 3,13* – 20 1,23* – 69
VAS 41 58,55* 43 71,55* 75
* statistically significant difference compared to the baseline (p < 0.05).
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provement), «self-care» (7.85 %), «usual activi-
ties» (7.06 %), «pain/discomfort» (5.25 %) and 
«anxiety/depression» category (9.74%) improve-
ments (p < 0,05).
Based on contemporary data [9, 10], 
PRGFT was included in the combined treat-
ment scheme post PDT-course to stimulate epi-
thelialization of the wound defects in patients 
of the 2nd group. The effectiveness of the pro-
posed algorithm was confirmed by the improve-
ment of all categories of the EuroQol scale: 
«mobility» — by 18 %, «self-care» — by 9 %, 
«usual activities» — by 9 %, «pain/discomfort» 
15 % and «anxiety/depression» categories by 
20 % (p < 0.05). 
Advantages of using PDT and PRGFT in 
sequential stages of wound healing reveals new 
therapeutic perspectives in regenerative medi-
cine. This treatment scheme has obvious ad-
vantages compared to the traditional debride-
ment. Both components have demonstrated 
properties for active stimulation of cell prolife-
ration, differentiation and angiogenic potential. 
This approach permits healing time reduction, 
thus improving quality of life of DM patients. 
As limitations, only local wound status dy-
namic effects on quality of life were evaluated, 
while other general conditions were not consi-
dered in the current study, aspects envisaged 
in future studies.
CONCLUSIONS
Photodynamic and autologous plasma rich 
growth factors combined therapy is preferable 
vis-a-vis standard care in the treatment and 
improvement of quality of life in outpatients 
with diabetic foot syndrome.
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Introduction. Diabetic neuro- and angiopathy are major factors causing diabetic foot ulcers. Ischemia 
reduces oxygen and nutrients supply to wounds. In oxygen and nutrients deprived conditions, epithelial cells in 
wounds fail to sufficiently release important wound healing factors such as vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor (PDGF). In recent studies a pool of growth factors from autologous 
plasma rich growth factors were analyzed. The aim of the study is to evaluate the efficacy of combined photo-
dynamic (PDT) and autologous plasma rich growth factor therapy (PRGFT) on quality of life improvements in 
patients with diabetic foot syndrome. 
Materials and methods. 61 outpatients with type 2 diabetes mellitus and Wagner grade II diabetic foot 
syndrome were included in this study. Patients of the 1st group (n = 30) received standard therapy (ST), in the 
2nd group (n = 31) ST was supplemented by PDT and PRGFT. 
Results. Using PDT in combined therapeutic management of chronic ulcer in patients with DM resulted 
in complete purification of the wound surfaces during shorter time durations vis-a-vis standard therapy, 
thus influencing all quality of life indicators according to EuroQol scale, including the category of «mobility» 
(improvement by 2.72 %), «self-care» (by 7.85 %), «usual activities» (by 7.06 %), «pain/discomfort» (by 5.25 %) 
and «anxiety/depression» categories (by 19.74 %). PRGFT was included in the combined treatment scheme post 
PDT-course to stimulate epithelialization of wound defects in patients of the 2nd group. Efficacy of this combined 
algorithm was confirmed by overall EuroQol scale category improvements: «mobility» — by 18 %, «self-care» — 
by 9 %, «usual activities» — by 9 %, «pain/discomfort» 15 % and «anxiety/depression» categories by 20 %. 
Conclusions. Combined photodynamic and autologous plasma rich growth factor therapy is preferable to 
standard therapy in the therapeutic management and improvement of quality of life in outpatients with diabetic 
foot syndrome.
K ey  wor d s :  Diabetes mellitus, diabetic foot, photodynamic therapy, autologous plasma.
ДИНАМ²КА ЯКОСТ² ЖИТТЯ  
У ХВОРИХ З СИНДРОМОМ ДИАБЕТИЧНО¯ СТОПИ  
ПРИ КОМБ²НОВАНОМУ Л²КУВАНН² З ВИКОРИСТАННЯМ Ф²З²ОТЕРАП²¯  
ТА АУТОЛОГ²ЧНО¯ ПЛАЗМИ
Харченко Т. О.1, Мелеховець О. К.1, Мелеховець Ю. В.1,  
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Вступ. Діабетична нейропатія та ангіопатія – це основні патогенетичні фактори, що призводять 
до утворення трофічних виразок у хворих на цукровий діабет. Ішемія призводить до гіпоксії та недо-
статнього вивільнення факторів росту ендотелію судин (VEGF) та тромбоцитарного фактору (PDGF) 
епітеліальними клітинами. Згідно сучасних досліджень, для загоєння трофічних виразок актуаль-
ним є використання аутологічної плазми, збагаченої факторами росту. 
Мета дослідження — оцінити ефективність комбінованої фотодинамічної терапії (ФДТ) та плаз-
мотерапії, збагаченої факторами росту (PRGFT) для покращення якості життя пацієнтів із синдромом 
діабетичної стопи. 
Матеріали і методи. У дослідження включено 61 пацієнт з цукровим діабетом 2 типу з синдро-
мом діабетичної стопи II ступеня за Wagner. Пацієнти 1-ї групи (n = 30) отримували стандартну тера-
пію (СТ), у 2-й групі (n = 31) СТ була доповнена ФДТ та PRGFT. 
Результати. Використання ФДТ у комбінованому лікуванні хронічних виразок у хворих на ЦД по-
кращує очищення ранової поверхні у більш короткі терміни порівняно із СТ, що впливає на показники 
якості життя за шкалою EuroQol, категорію «фізична активність» поліпшило на 2,72 %, «самообслуго-
вування» — на 7,85 %, «побутова активність» — на 7,06 %, «біль/дискомфорт» — на 5,25 % та категорії 
«тривожність/депресія» — на 19,74 %. PRGFT було включено в комбіновану схему лікування після ФДТ 
для стимулювання епітеліалізації ранового дефекту у пацієнтів 2-ї групи. Ефективність заданого 
алгоритму підтверджено покращенням показників категорій шкали EuroQol: «фізична активність» — 
на 18 %, «самообслуговування» — на 9 %, «побутова активність» — на 9 %, «біль/дискомфорт» на 15 % 
та «тривожність/депресія» на 20 %. 
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Висновки. Комбінована фотодинамічна терапія та плазмотерапія, збагачена факторами росту, 
є ефективнішою, у порівнянні з стандартною терапією, у лікуванні та покращенні якості життя хворих 
із синдромом діабетичної стопи.
Ключові слова: цукровий діабет, діабетична стопа, фотодинамічна терапія, аутологічна плазма.
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ПРИ КОМБИНИРОВАННОМ ЛЕЧЕНИИ С ИСПОЛЬЗОВАНИЕМ ФИЗИОТЕРАПИИ  
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Введение. Диабетическая нейропатия и ангиопатия – это основные патогенетические факторы, 
которые приводят к образованию трофических язв у больных сахарным диабетом. Ишемия приводит 
к гипоксии и недостаточному высвобождению факторов роста эндотелия сосудов (VEGF) и тробоци-
тарного фактора (PDGF) эпителиальными клетками. Согласно современным исследованиям, с целью 
заживления трофических язв, является актуальным использование аутологической плазмы, обога-
щенной факторами роста. 
Цель исследования — оценить эффективность комбинированной фотодинамической терапии 
(ФДТ) и плазмотерапии, обогащенной факторами роста (PRGFT) для улучшения качества жизни па-
циентов с синдромом диабетической стопы. 
Материалы и методы. В исследование включено 61 пациент с сахарным диабетом 2 типа с син-
дромом диабетической стопы II степени по Wagner. Пациенты 1-й группы (n = 30) получали стандарт-
ную терапию (СТ), во 2-й группе (n = 31) СТ была дополнена ФДТ и PRGFT. 
Результаты. Применение ФДТ в комбинированном лечении хронических язв у больных СД улуч-
шает очищение раневой поверхности в более короткие сроки, по сравнению с СТ, улучшает показа-
тели качества жизни по шкале EuroQol, категорию «физическая активность» улучшило на 2,72 %, 
«самообслуживания» — на 7,85 %, «бытовая активность» — на 7,06 %, «боль/дискомфорт» — на 5,25 % 
и категории «тревожность/депрессия» — на 19,74 %. PRGFT была включена в комбинированную схему 
лечения после ФДТ для стимуляции епителиализации раневого дефекта у пациентов 2-й группы. 
Эффективность данного алгоритма была подтверждена улучшением показателей категорий шкалы 
EuroQol: «физическая активность» — на 18 %, «самообслуживания» — на 9 %, «бытовая активность» — 
на 9 %, «боль/дискомфорт» на 15% и «тревожность/депрессия» на 20 %. 
Выводы. Комбинированная фотодинамическая терапия и плазмотерапия, обогащённая фактора-
ми роста является более эффективной, по сравнению со стандартной терапией, в лечении и улучше-
нии качества жизни амбулаторных больных с синдромом диабетической стопы.
Ключевые слова: сахарный диабет, диабетическая стопа, фотодинамическая терапия, аутологиче-
ская плазма.
